EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections

Maura Kreiser iD, Sarah Al Mansi iD, Ismaeel Yunusa iD, Caroline Derrick iD, P Brandon Bookstaver iD, Majdi N Al-Hasan, Yorika Hammett, Morgan Pizzuti iD

Pharmacy · 14.03.2026 · 14 (2) · 48

DOI: 10.3390/pharmacy14020048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy, online erschienen am 14.03.2026. Verfasst von Maura Kreiser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Prisma Health Richland, Columbia, SC 29203, USA. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of General Medical Sciences of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Well-designed randomized controlled trials (RCTs) have demonstrated safe and effective use of oral antimicrobial therapy for bone and joint infections. Application of data for implementation into real-world practice, however, has inherent challenges. This retrospective cohort study compared real-world use of intravenous versus oral antimicrobial therapy in bone and joint infections within a large healthcare system comprising both academic and community medical centers. The primary outcome was the proportion of treatment failure. Key secondary outcomes included the proportion of patients with logistical failure and risk factors associated with treatment and logistical failure. Among 166 patients included, 136 (82%) and 30 (18%) received predominantly intravenous and oral antimicrobial therapy, respectively. Treatment failure occurred in (77/121) 64% versus (18/25) 72% of patients in the intravenous and oral antimicrobial groups (p = 0.491; OR, 1.38; 95% CI, 0.56–3.33). Logistical failure occurred in 29% versus 47% of patients in the intravenous and oral antimicrobial groups (p = 0.150; OR, 1.93; 95% CI 0.79–4.70). Risk factors for treatment failure included peripheral vascular disease (OR, 2.61; 95% CI 1.02–7.80) and higher Charlson Comorbidity Index scores (OR, 1.18; 95% CI 1.04–1.36). Similar to previously published RCTs, treatment failure appeared comparable between groups; however, oral antimicrobial therapy was overall underutilized.

Schlagwörter

Stichwörter der Autor:innen

Staphylococcus aureusosteomyelitisseptic arthritisspinal infections

Autor:innen und Institutionen

  • Prisma Health Richland, Columbia, SC 29203, USA.
  • Prisma Health Tuomey, Sumter, SC 29150, USA.
  • Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA.
  • School of Medicine, University of South Carolina, Columbia, SC 29203, USA.

ORCID-Profile: Maura Kreiser, Sarah Al Mansi, Ismaeel Yunusa, Caroline Derrick, P Brandon Bookstaver, Morgan Pizzuti

Förderung

  • National Institute of General Medical Sciences of the National Institutes of Health

Zitieren

APA

Kreiser, M., Al Mansi, S., Yunusa, I., Derrick, C., Bookstaver, P. B., Al-Hasan, M. N., Hammett, Y., & Pizzuti, M. (2026). Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections. Pharmacy, 14(2), 48. https://doi.org/10.3390/pharmacy14020048

Vancouver

Kreiser M, Al Mansi S, Yunusa I, Derrick C, Bookstaver PB, Al-Hasan MN, et al. Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections. Pharmacy. 2026;14(2):48. doi:10.3390/pharmacy14020048

BibTeX
@article{Kreiser2026,
  author = {Kreiser, Maura and Al Mansi, Sarah and Yunusa, Ismaeel and Derrick, Caroline and Bookstaver, P Brandon and Al-Hasan, Majdi N and Hammett, Yorika and Pizzuti, Morgan},
  title = {Real-World Comparison of Intravenous vs. Oral Antimicrobial Therapy for Bone and Joint Infections},
  journal = {Pharmacy},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {48},
  doi = {10.3390/pharmacy14020048}
}
Kostenlos starten →